BPC-157
Repair signals in rodents are not a tendon treatment in humans. Small human reports do not establish efficacy, an approved indication, or long-term safety. FDA flags immunogenicity, peptide impurities and insufficient safety information for compounded BPC-157.
No validated routine human dose, injection location, cycle or BPC-157/TB-500 combination is established. Keep rehabilitation, sleep and nutrition separate from experimental-drug claims. A purity certificate does not establish clinical safety.
